ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor t…